FDA Statement: Original Opana ER Relisting Determination. The U.S. Food and Drug Administration (FDA) today responded to a petition and decided that the original formulation of Opana ER (oxymorphone hydrochloride) Extended-Release Tablets was not withdrawn from the market for reasons of safety or effectiveness.
The heart is a vital organ located in the center of the chest with a slight tilt to the left. Using rhythmic muscle contractions, it circulates blood through veins and arteries, which supplies tissues with oxygenated blood and disposes waste.
The heart is a vital organ located in the center of the chest with a slight tilt to the left. Using rhythmic muscle contractions, it circulates blood through veins and arteries, which supplies tissues with oxygenated blood and disposes waste. Read More.